In vivo generation of CD19 CAR T cells for the treatment of mouse systemic lupus erythematosus
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.117256 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Haojun Xie und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Chi…. Hauptthemen laut MEDLINE: Antigens, CD19, Lupus Erythematosus, Systemic, B-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: Systemic lupus erythematosus (SLE) is a severe autoimmune disease with significant health impacts, yet effective therapies remain elusive. Recent advances underscore the promise of chimeric antigen receptor (CAR) T-cell therapy for SLE. However, conventional CAR T cells manufacturing is complex, limiting its clinical application. METHODS: To overcome the limitations, we developed an in vivo engineered CAR-T system using CD5-targeted lipid nanoparticles (aCD5-CD19/LNP) delivering CD19-directed CAR mRNA. RESULTS: aCD5-CD19/LNP efficiently generates functional CAR T cells capable of targeting CD19+ B cells in vitro. In the MRL/lpr murine SLE model, aCD5-CD19/LNP-generated CAR T cells achieved robust B cell depletion, particularly eliminating pathogenic splenic plasmablasts (CD19+CD20-CD27+) and switched memory B cells (CD19+CD20+CD27+IgD-). This targeted depletion reduced autoreactive antibodies, reduced proinflammatory cytokines, and attenuated histopathological damage in renal and dermal tissues. Critically, this in vivo strategy induced sustained remission without requiring lymphodepletion preconditioning or ex vivo cell manipulation. CONCLUSION: Our findings support in vivo-generated CAR T cells as a potentially clinically viable, effective modality for SLE, offering a scalable pathway toward curative immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China; The First Affiliated Hospital of Guangzhou Medical University, Gua…
- Department of Laboratory Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China.
- Shanghai RNACure Biopharma Co., Ltd, Shanghai, China.
- The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
- Hetao Institute of Guangzhou National Laboratory, Shenzhen, Guangdong, China.
- Department of Rheumatology and Immunology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Xie, H., Chen, D., Lin, Z., Luo, Q., Chen, W., Zhang, G., Yang, G., Zhou, T., Fu, T., Chen, Z., Lu, J., Li, Z., Jie, H., Lin, J., & Wang, Z. (2026). In vivo generation of CD19 CAR T cells for the treatment of mouse systemic lupus erythematosus. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117256
Vancouver
Xie H, Chen D, Lin Z, Luo Q, Chen W, Zhang G, et al. In vivo generation of CD19 CAR T cells for the treatment of mouse systemic lupus erythematosus. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.117256
BibTeX
@article{Xie2026,
author = {Xie, Haojun and Chen, Daxiang and Lin, Ziyun and Luo, Qi and Chen, Wenfang and Zhang, Guiyang and Yang, Gang and Zhou, Tingyan and Fu, Tianyang and Chen, Zheng and Lu, Jing and Li, Zonghong and Jie, Hongyu and Lin, Jinzhong and Wang, Zhongfang},
title = {In vivo generation of CD19 CAR T cells for the treatment of mouse systemic lupus erythematosus},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.117256}
}
EUVIMED